Corbus Pharmaceuticals (CRBP) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Rallybio (RLYB) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, gaining 280.4% versus a loss of 76.6%. Over five years, CRBP leads with a -84.2% price change compared with -87.5% for RLYB. Corbus Pharmaceuticals is the larger company by market cap ($87.4 million vs $86.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | RLYB |
|---|---|---|
| Share price | $4.52 | $16.28 |
| Market cap | $87.42M | $86.49M |
| 1-day change | +4.39% | -2.95% |
| YTD return | -44.47% | +196.65% |
| 1-year return | -76.60% | +280.37% |
| 5-year return | -84.16% | -87.46% |
| P/E ratio (TTM) | — | 2.03 |
| EPS (TTM) | $-6.11 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $858.00K |
| Revenue growth (YoY) | — | +34.91% |
| Net income (latest FY) | $-78.54M | $-8.98M |
| Operating margin | — | -3853.61% |
| Net margin | — | -1046.39% |
| 52-week high | $20.56 | $17.57 |
| 52-week low | $4.22 | $3.67 |
| Distance from 52-week high | -78.02% | -7.36% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +652.88% | — |
| Average volume | 825.10K | 15.38K |
| Shares outstanding | 19.34M | 5.31M |
| Employees | 36 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed CRBP by 357.0 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
CRBP vs RLYB FAQ
Which is bigger, Corbus Pharmaceuticals or Rallybio?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $87.42M compared with $86.49M for Rallybio (RLYB).
Which stock has performed better over the past year, CRBP or RLYB?
RLYB returned +280.37% over the past 12 months, compared with -76.60% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.